Invivoscribe Technologies, Inc.
Invivoscribe® is a comprehensive partner for CDx development. For 20+ years, we have standardized molecular assays for hematologic malignancies. Our facility is FDA-registered and ISO 13485-certified. We offer CE-IVD- and RUO-NGS assays and bioinformatics for B- & T-clonality — US validations are ongoing. Additionally, our reagents are used in the study of MRD and the tracking of immunotherapies. Our network of ISO 15189 compliant labs in the US, Europe, & Asia provide clinical and research services to identify and track actionable somatic mutations throughout the course of disease.